3 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
The primary objective is to show that eplerenone treatment reduces progression of disease in presymptomatic PLN R14del-carriers
Approved WMOCompleted
To compare the effects of various upper extremity positions on the sagittal spinal alignment, to determine which position corresponds the most with the neutral position and to determine which position is the most reliable across repeated…